LAS VEGAS, NV, June 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT), has launched its advanced proprietary supplement for dogs, Canine All-in-One, a daily dose formulation, patterned after its highly successful product for horses, Equine All-In-One. Canine All-In-One has been created by combining its top-selling Canine Regen product with strategic additional all natural botanical ingredients to be more comprehensive, by addressing a greater array of health issues, and more economical, by eliminating the need to purchase multiple individual vitamins, nutrients and organ-specific supplements. The components of Canine All-In-One are known to positively affect mitochondrial energy production, nutrient uptake and processing, joint function, immunological response, pain relief, blood flow dynamics, temperament, and hair quality.
Dog owners who utilize this supplement report striking and rapid improvement especially in older dogs who had displayed significant signs of aging, such as low energy, slow recovery from exercise, decreased mobility, prolonged sleeping patterns, memory loss, less responsiveness and decreased appetite. Although the rejuvenation effect is more dramatic in aging animals, dogs of all ages and breeds demonstrate an improvement in coat luster and texture, overall energy and disposition.
It is believed that these beneficial effects could be the result of primitive cell activation particularly in the brain and skin where scientists have identified resident stem cells in regions that control mood and the growth of hair. Further reports among consumers have indicated that even dogs that cannot be helped by traditional methods in their twilight years are observed to gain more vitality, mobility, and cognition within days.
According to a report published by GrandviewResearch.com, ‘In recent years, owners across the globe have been spending significantly on their pets’ well-being and nutrition…,” further indicating: “The global pet supplements market size was valued at USD 1.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030. The rise in pet humanization has led to consumers spending significantly on their food, supplements, toys, accessories, and other related products to keep them active, healthy, and happy. According to a report published by the American Pet Products Association (APPA), in 2021, dog, cat, and bird owners spent around USD 109.6 billion on these animals in the U.S. These market trends are driving the demand for these products.”
About Canine All-In-One –Canine All-in-One is a balanced formulation of selected natural ingredients designed to achieve maximum benefit and ensure safety in all designated species. Canine Regen and its derivatives have a proven eight-year record of safety and success, with no adverse effects reported by consumers.
BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, anti-viral activity and immune system defense; resistance to stress; endurance; recovery from injury, illness and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best worldwide sources and utilize proprietary methods of enhancing the bioavailability of nutrients. The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses. Additional human products, to be introduced soon, are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; and improve overall emotional and physical wellness. BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Additional information can be found at www.shopbioadaptives.com or in our SEC filings at
https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Contact: Investor Relations BioAdaptives, Inc. (702) 659-8829 info@bioadaptives.com
As we move toward the end of Q2, it’s time to start thinking about earnings. Looking back at the quarter, analysts are predicting earnings growth of 8%, which may rise to 11% heading into next year. It’s a rosy picture, but it’s also not a sure thing. GDP contracted in Q1, by nearly 1.5%, and some estimates are showing 0% growth in Q2. Such results would meet the technical definition of a recession – and recession is hardly the usual environment to find robust earnings growth. Looking at current
Nuclear submarine supplier to be sold to US buyer after diplomatic row Russian default expected within days Retail sales volumes down 0.5pc in May FTSE 100 rises strongly Ambrose Evans-Pritchard: The pro-Brussels establishment is painting Brexit as an economic disaster to reverse it Sign up here for our daily business briefing newsletter
At current levels, investors need a 7% to 8% return just to preserve their wealth.
Tesla plant near Shanghai is going to shut down temporarily, according to reports. On Wednesday, Reuters reported that Tesla (ticker: TSLA) will shut down production in China for a couple of weeks at the start of July to upgrade equipment. Tesla didn’t return a request for comment.
“Time is running out for cash-burning companies kept afloat with easy access to capital,” New Constructs CEO David Trainer said in a Thursday research note.
(Bloomberg) -- Robinhood Markets Inc. faced a more dire situation during the height of last year’s meme-stock frenzy than executives at the online brokerage let on publicly, according to a report from top Democrats on a key congressional committee. Most Read from BloombergSupreme Court Overturns Roe, Transforming Abortion-Rights FightStocks Roar Back With Best Week in a Month: Markets WrapJustice Kavanaugh Says States May Not Bar Travel to Obtain an AbortionProtest Latest: NY, DC Marches Grow as
Yahoo Finance Live anchors discuss the possible acquisition of Zendesk.
Bitcoin bear markets aren't unusual. But cryptocurrencies have never faced such an aggressive Federal Reserve. Welcome to the crypto ice age.
Dividend stocks are the new darlings in S&P 500. But investors are getting burned on those stocks, too.
Shares of the specialty pharmaceutical company Bausch Health Companies (NYSE: BHC) are surging today in response to the news that Joseph Papa has resigned from the board of directors effective immediately. Over the past six years, Papa has been instrumental in lowering the company's sky-high debt and keeping it out of bankruptcy court. Bausch said in a statement Thursday evening that billionaire hedge fund manager John Paulson will fill the vacant board position.
The Dow Jones moved higher as yields fell. Tesla stock skidded after CEO Elon Musk voiced a warning. A Warren Buffett stock rose.
High-yield dividend stocks are a major component of my stock portfolio. Here are three income stocks that have room for solid gains in the next year and even better gains over the long run. The blue-chip business development company (BDC) Main Street Capital (NYSE: MAIN) has held up better than the S&P 500 index, which is down 21% so far this year.
The drop is exciting some Berkshire investors because the stock now trades for 1.3 times Barron's estimate of its June 30 book value, compared with more than 1.5 times at its March high.
(Bloomberg) -- The S&P 500 Index may have another 24% to fall by year-end, if the past 150 years of financial-market history are any guide.Most Read from BloombergJuul’s Vaping Products Are Ordered Off the Market in the USThese Are the World’s Most Liveable Cities in 2022Elon Musk Says New Tesla Plants Are ‘Money Furnaces’ Losing BillionsRecession Worries Boost Treasuries; Stocks Advance: Markets WrapThe World’s Bubbliest Housing Markets Are Flashing Warning SignsThat’s according to Societe Gene
Shares in Polestar Automotive Holding UK PLC jumped 16% on their first day of trading Friday, after the Swedish electric-vehicle maker completed a merger with a special-purpose acquisition company amid plans to expand globally. Polestar agreed to be acquired by blank-check company Gores Guggenheim in September. The auto maker is a unit of Volvo Car AB, which in turn is owned by Zhejiang Geely Holding Group Co. of China.
Shares in the biggest U.S. banks rallied on Friday after they passed the Federal Reserve's annual health check, but Bank of America underperformed with test results implying it needs a larger-than-expected capital buffer, which could limit share buybacks and dividends. While the broader equity market also rallied on Friday, Wells Fargo & Co, up 7.5%, was the biggest gainer among the 34 lenders that underwent the Fed's so-called stress test, which measures how they would fare in a hypothetical severe economic downturn. The group would have roughly twice the capital required under Fed rules in the downturn scenario, it said.
Shares of Meta Platforms (NASDAQ: META), the parent company of Facebook, were rising quickly today on seemingly no company-specific news. Instead, a rebound in the tech sector appears to be sending Meta's stock higher today. The tech stock had gained 5.8% as of 1:22 p.m. ET on Friday.
High inflation could be here to stay. Make the necessary adjustments.
ConocoPhillips ( NYSE:COP ) stock is about to trade ex-dividend in 2 days. The ex-dividend date is one business day...
U.S. stock indexes moved more than 2% higher, as investors shifted their views about central bank policy after weak economic data.